This brand name is authorized in Mexico
The drug DERFINA contains one active pharmaceutical ingredient (API):
|
1
Butenafine
UNII R8XA2029ZI - BUTENAFINE HYDROCHLORIDE
|
|
Butenafine is a benzylamine derivative with a mode of action similar to that of the allylamine class of antifungal drugs. Butenafine HCl is hypothesized to act by inhibiting the epoxidation of squalene, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. It is indicated for the topical treatment of the dermatologic infection, tinea (pityriasis) versicolor due to M. furfur (formerly P. orbiculare). |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D01AE23 | Butenafine | D Dermatologicals → D01 Antifungals for dermatological use → D01A Antifungals for topical use → D01AE Other antifungals for topical use |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: MX | Comisión Federal para la Protección contra Riesgos Sanitarios | Identifier(s): 026M2007 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
